SpringWorks Therapeutics announced on November 7, 2024, that long-term efficacy and safety data from the Phase 3 DeFi trial of nirogacestat in adults with progressing desmoid tumors will be presented. The data, with an August 2024 cutoff, showed further reductions in tumor size and an increase in objective response rate (ORR) with additional partial and complete responses.
The longer-term treatment with nirogacestat was associated with sustained improvements in desmoid tumor symptoms, including pain, and a consistent safety profile. The median duration of nirogacestat treatment in these patients reached 33.6 months, extending from the 20.6 months reported at the primary analysis in April 2022.
These findings reinforce OGSIVEO's durable clinical benefit and safety profile, supporting its position as a systemic standard of care for adult patients with desmoid tumors. The data provides valuable insights for clinicians on the long-term use of this medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.